VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral Leishmaniasis

Bioluminescence imaging of chronicTrypanosoma cruziinfections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection

(2014) Michael D. Lewis et al.   CELLULAR MICROBIOLOGY

Leishmaniasis in immunosuppressed individuals

(2014) J. van Griensven et al.   CLINICAL MICROBIOLOGY AND INFECTION

Sequence variation in CYP51A from the Y strain ofTrypanosoma cruzialters its sensitivity to inhibition

(2014) Tatiana S. Cherkesova et al.   FEBS LETTERS

Randomized Trial of Posaconazole and Benznidazole for Chronic Chagas' Disease

(2014) Israel Molina et al.   NEW ENGLAND JOURNAL OF MEDICINE

Design or screening of drugs for the treatment of Chagas disease: what shows the most promise?

(2013) Galina I Lepesheva   Expert Opinion on Drug Discovery

Complexes ofTrypanosoma cruziSterol 14α-Demethylase (CYP51) with Two Pyridine-based Drug Candidates for Chagas Disease

(2013) Tatiana Y. Hargrove et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

New, Combined, and Reduced Dosing Treatment Protocols Cure Trypanosoma cruzi Infection in Mice

(2013) J. M. Bustamante et al.   JOURNAL OF INFECTIOUS DISEASES

VNI Cures Acute and Chronic Experimental Chagas Disease

(2013) Fernando Villalta et al.   JOURNAL OF INFECTIOUS DISEASES

An Unfolding Tragedy of Chagas Disease in North America

(2013) Peter J. Hotez et al.   PLoS Neglected Tropical Diseases

Synthesis and antikinetoplastid activities of 3-substituted quinolinones derivatives

(2012) Davide Audisio et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Organocatalytic, Enantioselective Synthesis of VNI: A Robust Therapeutic Development Platform for Chagas, a Neglected Tropical Disease

(2012) Mark C. Dobish et al.   ORGANIC LETTERS

CYP51 structures and structure-based development of novel, pathogen-specific inhibitory scaffolds

(2012) Tatiana Y. Hargrove et al.   International Journal for Parasitology-Drugs and Drug Resistance

Successful Treatment of Old World Cutaneous Leishmaniasis Caused byLeishmania infantumwith Posaconazole

(2011) A. E. Paniz Mondolfi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Sterol 14alpha-Demethylase (CYP51) as a Therapeutic Target for Human Trypanosomiasis and Leishmaniasis

(2011) Galina I. Lepesheva et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Substrate Preferences and Catalytic Parameters Determined by Structural Characteristics of Sterol 14α-Demethylase (CYP51) fromLeishmania infantum

(2011) Tatiana Y. Hargrove et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Structural complex of sterol 14α-demethylase (CYP51) with 14α-methylenecyclopropyl-Δ7-24, 25-dihydrolanosterol

(2011) Tatiana Y. Hargrove et al.   JOURNAL OF LIPID RESEARCH

Design and preparation of sterol mimetics as potential antiparasitics

(2010) Federica Gigante et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Structural Insights into Inhibition of Sterol 14α-Demethylase in the Human PathogenTrypanosoma cruzi

(2010) Galina I. Lepesheva et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Conazoles

(2010) Jan Heeres et al.   MOLECULES

Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents

(2009) Roger J. M. Brüggemann et al.   CLINICAL INFECTIOUS DISEASES

Cutaneous leishmaniasis treated with itraconazole

(2009) A. Baroni et al.   Dermatologic Therapy

Crystal Structures of Trypanosoma brucei Sterol 14α-Demethylase and Implications for Selective Treatment of Human Infections

(2009) Galina I. Lepesheva et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Ergosterol biosynthesis and drug development for Chagas disease

(2009) Julio A Urbina   MEMORIAS DO INSTITUTO OSWALDO CRUZ